← Leaderboards
Arthur Thomas Suckow
Dtx Pharma, Llc
$1,392,248
Attributed
$1,548,730
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $847.8K · FY2019–21$1M$750K$500K$250K$0
'19
'20
'21
Funding mix
By agency
NIH$1,548,730 · 5
By mechanism
R43$1,235,765 · 4
R41$312,965 · 1
Top collaborators
- Brian C. Kraemer2 shared
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposTechnologyUptakeTissuesCellsNeuronsLiverSmall Interfering RnaSafetyIn VivoGenerationsFatty AcidsGenesBiologicalNerve DegenerationEvaluationSmall Business Innovation Research GrantDoseKnock-DownDesignMouse ModelMrna ExpressionMessenger RnaLead
Grant awards (6)
Reversal of Tau Pathology with MSUT2 siRNA Conjugates$99,938
R41 · FY2021 · AG · contact PI
Development of PMP22 siRNA Conjugates for Treatment of Charcot-Marie-Tooth Disease Type 1A$387,925
R43 · FY2020 · NS · contact PI
Reversal of Tau Pathology with MSUT2 siRNA Conjugates$213,027
R41 · FY2020 · AG · contact PI
Systemic Characterization of Novel Lipidated siRNA Conjugates$321,555
R43 · FY2019 · TR · contact PI
Development of Conjugated Oligonucleotide Therapeutics for Neuronal Disease$301,212
R43 · FY2019 · TR · contact PI
Generation of potent, safe and deliverable human Tau targeting siRNA for treatment of Tauopathies$225,073
R43 · FY2019 · AG · contact PI